ILMN up +3.52% percent Today $ILMN High is at 189.46 and the Low 182.96 with current volume of 208,722.
Recent News posted below.
Illumina Inc ILMN other info.
http://investorshangout.com/Illumina-ILMN-54443/
ILMN Illumina Inc Recent Headline News
Global miRNA Research and Diagnostics Markets Report 2014
M2 - 23 mins ago
Research and Markets (http://www.researchandmarkets.com/research/fjgcv3/mirna_research) has announced the addition of the "miRNA Research and Diagnostics Markets" report to their offering. This report considers the diagnostic promise of non-coding RNA molecules, with a particular focus on the microRNAs. miRNAs (MicroRNAs) are short, single stranded RNAs that regulate mRNA expression at the post-transcriptional level. These small bits of RNA, members of a class of non-translated molecules that donot produce protein, shut off gene transcription by base pairing with the target molecules. They are now recognized as pivotal regulators of gene expression; including development, proliferation, differentiation, and apoptosis and serving widespread functions as regulatory molecules in post-transcriptional gene silencing. As the report details, alarge number of companies, both small biotechs and big pharmaceutical companiesare committed to miRNA diagnostics. As part of its coverage of this topic, this report includes the following: - Overview of miRNAs - Positive Factors for miRNA Diagnostic Technologies - Negative Factors - miRNAs and Neurological Disorders - miRNA and Metastatic Brain Lesions - Prostate Cancer Screening and miRNAs - miRNAs and Resistance to Anti-Cancer Drugs - Theoretical Limitations - Discussion of Patent Issues - Interviews with Industry Experts - Market Estimate As part of its coverage, the miRNA offerings and products in developments in the following companies are profiled in detail: - Agilent Technologies - AMSBIO - Applied Biosystems - DiamiR, LLC - Dicerna - Eisai Biomarkers and Personalized Medicine - Diagnostics - Genomic Health Inc. - Gensignia - GlaxoSmithKline Discovery and Molecular Toxicology - Groove Biopharma (formerly Mirina) - Hologic-Gen Probe Inc. - Illumina, Inc. - Isis Pharmaceuticals - Mello Biotechnology Inc. - Microlin Bio - MiRagen Therapeutics - MiRNA Therapeutics - Novartis - Pacific Edge Biotechnology - Prolias Technologies - Regulus Therapeutics - Rosetta Genomics - Santaris Pharma A/S - Sirnaomics, Inc. - Somagenics - Diagnostics: Small RNA Assays and Biomarker Validation - Tekmira Pharmaceuticals Corporation - Thermadiag - Thermo Fisher Scientific, Inc. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Current State of the Art 4. Companies Developing microRNA Diagnostic Technologies 5. Market Estimates and Forecasts 6. Interviews with Industry Experts: Biomarkers 7. The Future of miRNA-Based Diagnostics For more information visit http://www.researchandmarkets.com/research/fj...a_research
ISIS: 50.39 (+1.38), A: 40.70 (-0.54), TKMR: 17.04 (-0.20), ILMN: 189.21 (+6.30), RGLS: 17.87 (+1.02), GSK: 46.16 (+0.28), HOLX: 26.58 (+0.21), GHDX: 32.88 (+1.20), NVS: 95.43 (+1.05)
Global Next Generation Sequencing (Genome/Exome Sequencing/DNA Sequencing) Market Forecasts and Opportunities, 2020 - Updated Report
M2 - Tue Nov 18, 4:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/h58jql/next_generation) has announced the addition of the "Next Generation Sequencing (Genome/Exome sequencing/DNA sequencing) Global market - Forecast to 2020" report to their offering. Next generation sequencing market is one of the fastest growing segments in the genomics market with an estimated CAGR of around 17.0% in the next five years. The major factors such as rapid adoption of this technology by researchers and its usability as a substitute of microarray technology in addition to its higher throughput, increased accuracy, and affordable costs are driving the next generation sequencing market growth. However, factors such as reducing capital expenditure from academic institutions and huge dependability on grants funding from the government are hampering the next generation sequencing market growth. In addition, the analysis of large amount of data generated by sequencers, and data storage and management is posing a major challenge. The growth opportunities of this market include cloud computing, rising demand for pre-sequencing, developments in NGS fully integrated instruments and rising nanopore sequencing technology. There is a huge opportunity for this technology in the field of drug discovery, personalized medicine, agricultural and animal research. The North American region accounts for the largest share of the next generation sequencing market. The European and Asian markets are also expected to grow due to the favorable funding from the government to adopt this technology. The major factors contributing to this market growth include rising adoption by new customers, rising adoption of high-throughput sequencing platforms by government organizations such as Biotechnology and Biological Sciences Research Council (BBSRC) (U.K.) and NHGRI (National Human Genome Research Institute) (U.S.). Key Topics Covered: 1 Executive Summary 2 Introduction 3 Market Analysis 4 Next Generation Sequencing Market, By Products 5 Next Generation Sequencing Market Value And Volume Analysis, By Technology 6 Next Generation Sequencing Market, By End Users/Laboratories 7 Next Generation Sequencing Market Value And Volume Analysis, By Application Area 8 Geographic Analysis 9 Company Developments 10 Major Player Profiles - Agilent Technologies, Inc. - Beijing Genome Institute - Biomatters, Ltd. - Genomatix Software Gmbh - Illumina Inc. - Life Technologies Corp. - Pacific Biosciences of California Inc. - QIAGEN N.V - Roche Holding Ltd. - Strand Life Sciences Pvt. Ltd. For more information visit http://www.researchandmarkets.com/research/h5...generation
PACB: 6.95 (-0.03), A: 40.70 (-0.54), ILMN: 189.21 (+6.30)
bioMerieux and Illumina Enter Agreement to Co-Develop a Next-Generation Sequencing Solution for Epidemiological Monitoring of Bacterial Infections
Business Wire - Tue Nov 18, 12:00AM CST
bioMerieux, a world leader in the field of in vitro diagnostics, and Illumina (Nasdaq:ILMN), a world leader in genomics, announced they have signed an exclusive agreement to launch a next-generation sequencing (NGS) epidemiology solution for service labs. The two companies will jointly develop applications for microbiology sequencing technologies within a four-year renewable period.
ILMN: 189.21 (+6.30)
Stock Market Turns Mixed; Michaels Rallies To New High
at Investor's Business Daily - Mon Nov 17, 12:22PM CST
Stocks improved Monday afternoon, turning mixed. They have wavered amid news of Japan falling into a recession and a round of merger and acquisition activity. The Dow Jones industrial average rose 0.1%, lifted by UnitedHealth Group (UNH). The broader...
HAS: 55.98 (-0.39), LNKD: 223.74 (+0.46), FB: 74.59 (+0.35), UNH: 98.25 (+1.78), ILMN: 189.21 (+6.30), MIK: 21.83 (+0.18), DWA: 22.35 (+0.04)
Strength Seen in Geron (GERN): Stock Surges 19.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 8:25AM CST
Geron (GERN) was a big mover last session, with shares surging over 19% on the day.
BIIB: 305.77 (+3.35), GERN: 3.08 (+0.10), ILMN: 189.21 (+6.30), AFFX: 9.50 (+0.21)
Sequenta Enters Agreement with Illumina on In Vitro Diagnostic Kit for Sequencing-Based Minimal Residual Disease Testing
Business Wire - Mon Nov 17, 8:01AM CST
Sequenta, Inc., a biotechnology company developing clinical diagnostics based on immune cell receptor genes, today announced that the company has entered into an agreement with Illumina, Inc. (NASDAQ: ILMN). The purpose of the agreement is to commercialize an in vitro diagnostic (IVD) kit that will enable clinical laboratories to utilize Sequenta's next-generation sequencing (NGS)-based minimal residual disease (MRD) detection and quantification technology.
ILMN: 189.21 (+6.30)
Medical Stocks Tumble But Most Of IBD 50 Trading Well
at Investor's Business Daily - Fri Nov 14, 5:47PM CST
A few medical leading stocks have slid, but otherwise the IBD 50 remained in good shape last week. Illumina (ILMN) and Akorn (AKRX) have fallen below their buy points, while Alexion Pharmaceuticals (ALXN) and Celgene (CELG) exhibited some weakness of...
AKRX: 38.78 (+0.89), ALXN: 189.60 (+2.82), FFIV: 128.49 (+0.63), ILMN: 189.21 (+6.30), SPR: 41.49 (+0.42), AAPL: 114.66 (+0.67), ATHM: 41.81 (-1.04), BITA: 94.12 (+4.74), CELG: 105.97 (+1.61)
Stock Market Treads Water; Earnings Drive BitAuto
at Investor's Business Daily - Fri Nov 14, 3:21PM CST
Stocks struggled for direction for most of the day Friday amid upbeat data on retail sales and consumer sentiment. But the main indexes ultimately ended mildly higher. The Nasdaq edged up 0.2%, thanks to strength in software and solar issues. But...
NTES: 100.72 (-0.40), ILMN: 189.21 (+6.30), BITA: 94.12 (+4.74), CELG: 105.97 (+1.61)
Stocks Mixed; Amazon Jumps On Book Deal
at Investor's Business Daily - Fri Nov 14, 12:32PM CST
Stocks were mixed, but gained a small amount of ground in afternoon trading Friday. A better-than-expected retail sales report lifted Wall Street spirits in the stock market today. The Nasdaq gained 0.1%; the Dow Jones industrial average dropped...
BIIB: 305.77 (+3.35), AMZN: 328.43 (+5.38), HAL: 49.75 (+0.52), ILMN: 189.21 (+6.30), BITA: 94.12 (+4.74), BHI: 65.91 (+0.68), CELG: 105.97 (+1.61)
Sarepta Initiates Dosing for Study Evaluating Eteplirsen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:40PM CST
Sarepta (SRPT) announced that it has enrolled the first patient in an open label study on eteplirsen in non-ambulant Duchenne muscular dystrophy patients.
RNA: 11.37 (-0.42), SRPT: 15.57 (+0.23), ILMN: 189.21 (+6.30), CELG: 105.97 (+1.61)
Illumina Falls 1.03% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Nov 13, 4:25PM CST
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $183.84 to a high of $191.62. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $186.11 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ILMN: 189.21 (+6.30)
Ligand/Glaxo Seek EU Nod for Severe Aplastic Anemia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:00PM CST
Ligand Pharma (LGND) announced the submission of a Marketing Authorisation Application to the European Medicines Agency by its partner GlaxoSmithKline for Revolade.
LGND: 57.70 (+0.75), ILMN: 189.21 (+6.30), GSK: 46.16 (+0.28), CELG: 105.97 (+1.61)
Qiagen Partners with Novartis for Companion Diagnostics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 1:20PM CST
Qiagen N.V. (QGEN) has signed a master collaboration agreement with Novartis.
ICUI: 86.41 (+0.71), ILMN: 189.21 (+6.30), QGEN: 23.83 (+0.34), NVS: 95.43 (+1.05)
Alnylam Adds Hepatic Infectious Disease Drugs to Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:40PM CST
Alnylam (ALNY) expands its hepatic infectious disease pipeline with two new candidates, ALN-HDV (hepatitis delta viral) and ALN-PDL (chronic liver).
BIIB: 305.77 (+3.35), ALNY: 91.25 (+2.27), ILMN: 189.21 (+6.30), AMAG: 35.78 (+1.02)
Brand Timbre Develops Audio-Identity Platform for World's Largest Genomics Company
Marketwired - Wed Nov 12, 6:00AM CST
Brand Timbre LLC, a strategic sonic branding agency, has completed work on the first stage of a comprehensive audio-branding initiative for Illumina Inc. Illumina is an industry-leading life-sciences company that designs, develops and manufactures DNA and genetics sequencing machines used in labs throughout the world. Brand Timbre's multi-phase project includes an audio-branding strategy, an audio-identity profile that defines Illumina's sound, an audio logo, and product-sonification (sound design) assets for Illumina's sequencing instruments.
ILMN: 189.21 (+6.30)
Critical Alerts For Achillion Pharmaceuticals, Celldex Therapeutics, Kandi Technologies, Illumina and Advanced Micro Devices Released By InvestorsObserver
PR Newswire - Tue Nov 11, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for ACHN, CLDX, KNDI, ILMN and AMD.
KNDI: 14.82 (+0.65), AMD: 2.66 (-0.01), ACHN: 13.59 (+0.27), CLDX: 17.66 (-0.59), ILMN: 189.21 (+6.30)
Achillion Pharmaceuticals (ACHN) Looks Strong: Stock Up 27.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 7:44AM CST
Achillion Pharmaceuticals (ACHN) was a big mover last session, as the company saw its shares surge a little over 27% on the day
HSKA: 15.00 (-0.05), ACHN: 13.59 (+0.27), ILMN: 189.21 (+6.30), AFFX: 9.50 (+0.21)
Global Preimplantation Genetic Diagnosis (PGD for Chromosomal Aberrations, Aneuploidy Screening, Gender Selection, Single Gene Disorders, HLA Typing and X-linked Diseases) Market - Trends and Forecast to 2020
M2 - Tue Nov 11, 4:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/sm76mf/preimplantation) has announced the addition of the "Preimplantation Genetic Diagnosis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. Since the last two decades, preimplantation genetic diagnosis (PGD) has been used to detect chromosomal aneuploidy in low prognosis patients who undergo in-vitro fertilization (IVF). PGD is now being used to detect a broader range of indications due to advancements in the medical technology. These indications include chromosomal aberrations, genetic abnormalities, gender selection, HLA typing, X-linked diseases and single gene diseases. Demand for PGD is continuously increasing in patients who undergo IVF in the hope that it would improve the probability of live birth and reduce the chances of disabilities and genetic disorders in the offspring. This report provides in-depth analysis of the preimplantation genetic diagnosis market and its test types across various regions. Stakeholders in the report include diagnostic laboratories that provide PGD services, companies involved in the production of diagnosis kits and sequencers for PGD, and prospective market players planning to enter the market. The report comprises executive summary, which offers a market snapshot that covers the overall information about various types of tests in the PGD market. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Preimplantation Genetic Diagnosis Market Overview Chapter 4 Global Preimplantation Genetic Diagnosis Market, by Test Type Chapter 5 Preimplantation Genetic Diagnosis Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles Companies Mentioned: - Genea Ltd. - Genesis Genetics - Illumina, Inc. - Laboratory Corporation of America Holdings (LabCorp) - Natera, Inc. - PerkinElmer, Inc. - Quest Diagnostics, Inc. - Reproductive Genetics Institute - Reprogenetics LLC For more information visit http://www.researchandmarkets.com/research/sm...plantation
DGX: 63.45 (+0.41), LH: 100.71 (+0.63), ILMN: 189.21 (+6.30), PKI: 43.60 (+0.21)
Winning Stock Picking Ideas from Last Week's Jobs Report - Screen of the Week
Kevin Matras - Zacks Investment Research - Tue Nov 11, 3:18AM CST
Winning Stock Picking Ideas from Last Week's Jobs Report - Screen of the Week
CST: 42.76 (+0.85), JACK: 71.27 (+0.98), IHS: 132.26 (+1.06), ILMN: 189.21 (+6.30)
Recent News posted below.
Illumina Inc ILMN other info.
http://investorshangout.com/Illumina-ILMN-54443/
ILMN Illumina Inc Recent Headline News
Global miRNA Research and Diagnostics Markets Report 2014
M2 - 23 mins ago
Research and Markets (http://www.researchandmarkets.com/research/fjgcv3/mirna_research) has announced the addition of the "miRNA Research and Diagnostics Markets" report to their offering. This report considers the diagnostic promise of non-coding RNA molecules, with a particular focus on the microRNAs. miRNAs (MicroRNAs) are short, single stranded RNAs that regulate mRNA expression at the post-transcriptional level. These small bits of RNA, members of a class of non-translated molecules that donot produce protein, shut off gene transcription by base pairing with the target molecules. They are now recognized as pivotal regulators of gene expression; including development, proliferation, differentiation, and apoptosis and serving widespread functions as regulatory molecules in post-transcriptional gene silencing. As the report details, alarge number of companies, both small biotechs and big pharmaceutical companiesare committed to miRNA diagnostics. As part of its coverage of this topic, this report includes the following: - Overview of miRNAs - Positive Factors for miRNA Diagnostic Technologies - Negative Factors - miRNAs and Neurological Disorders - miRNA and Metastatic Brain Lesions - Prostate Cancer Screening and miRNAs - miRNAs and Resistance to Anti-Cancer Drugs - Theoretical Limitations - Discussion of Patent Issues - Interviews with Industry Experts - Market Estimate As part of its coverage, the miRNA offerings and products in developments in the following companies are profiled in detail: - Agilent Technologies - AMSBIO - Applied Biosystems - DiamiR, LLC - Dicerna - Eisai Biomarkers and Personalized Medicine - Diagnostics - Genomic Health Inc. - Gensignia - GlaxoSmithKline Discovery and Molecular Toxicology - Groove Biopharma (formerly Mirina) - Hologic-Gen Probe Inc. - Illumina, Inc. - Isis Pharmaceuticals - Mello Biotechnology Inc. - Microlin Bio - MiRagen Therapeutics - MiRNA Therapeutics - Novartis - Pacific Edge Biotechnology - Prolias Technologies - Regulus Therapeutics - Rosetta Genomics - Santaris Pharma A/S - Sirnaomics, Inc. - Somagenics - Diagnostics: Small RNA Assays and Biomarker Validation - Tekmira Pharmaceuticals Corporation - Thermadiag - Thermo Fisher Scientific, Inc. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Current State of the Art 4. Companies Developing microRNA Diagnostic Technologies 5. Market Estimates and Forecasts 6. Interviews with Industry Experts: Biomarkers 7. The Future of miRNA-Based Diagnostics For more information visit http://www.researchandmarkets.com/research/fj...a_research
ISIS: 50.39 (+1.38), A: 40.70 (-0.54), TKMR: 17.04 (-0.20), ILMN: 189.21 (+6.30), RGLS: 17.87 (+1.02), GSK: 46.16 (+0.28), HOLX: 26.58 (+0.21), GHDX: 32.88 (+1.20), NVS: 95.43 (+1.05)
Global Next Generation Sequencing (Genome/Exome Sequencing/DNA Sequencing) Market Forecasts and Opportunities, 2020 - Updated Report
M2 - Tue Nov 18, 4:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/h58jql/next_generation) has announced the addition of the "Next Generation Sequencing (Genome/Exome sequencing/DNA sequencing) Global market - Forecast to 2020" report to their offering. Next generation sequencing market is one of the fastest growing segments in the genomics market with an estimated CAGR of around 17.0% in the next five years. The major factors such as rapid adoption of this technology by researchers and its usability as a substitute of microarray technology in addition to its higher throughput, increased accuracy, and affordable costs are driving the next generation sequencing market growth. However, factors such as reducing capital expenditure from academic institutions and huge dependability on grants funding from the government are hampering the next generation sequencing market growth. In addition, the analysis of large amount of data generated by sequencers, and data storage and management is posing a major challenge. The growth opportunities of this market include cloud computing, rising demand for pre-sequencing, developments in NGS fully integrated instruments and rising nanopore sequencing technology. There is a huge opportunity for this technology in the field of drug discovery, personalized medicine, agricultural and animal research. The North American region accounts for the largest share of the next generation sequencing market. The European and Asian markets are also expected to grow due to the favorable funding from the government to adopt this technology. The major factors contributing to this market growth include rising adoption by new customers, rising adoption of high-throughput sequencing platforms by government organizations such as Biotechnology and Biological Sciences Research Council (BBSRC) (U.K.) and NHGRI (National Human Genome Research Institute) (U.S.). Key Topics Covered: 1 Executive Summary 2 Introduction 3 Market Analysis 4 Next Generation Sequencing Market, By Products 5 Next Generation Sequencing Market Value And Volume Analysis, By Technology 6 Next Generation Sequencing Market, By End Users/Laboratories 7 Next Generation Sequencing Market Value And Volume Analysis, By Application Area 8 Geographic Analysis 9 Company Developments 10 Major Player Profiles - Agilent Technologies, Inc. - Beijing Genome Institute - Biomatters, Ltd. - Genomatix Software Gmbh - Illumina Inc. - Life Technologies Corp. - Pacific Biosciences of California Inc. - QIAGEN N.V - Roche Holding Ltd. - Strand Life Sciences Pvt. Ltd. For more information visit http://www.researchandmarkets.com/research/h5...generation
PACB: 6.95 (-0.03), A: 40.70 (-0.54), ILMN: 189.21 (+6.30)
bioMerieux and Illumina Enter Agreement to Co-Develop a Next-Generation Sequencing Solution for Epidemiological Monitoring of Bacterial Infections
Business Wire - Tue Nov 18, 12:00AM CST
bioMerieux, a world leader in the field of in vitro diagnostics, and Illumina (Nasdaq:ILMN), a world leader in genomics, announced they have signed an exclusive agreement to launch a next-generation sequencing (NGS) epidemiology solution for service labs. The two companies will jointly develop applications for microbiology sequencing technologies within a four-year renewable period.
ILMN: 189.21 (+6.30)
Stock Market Turns Mixed; Michaels Rallies To New High
at Investor's Business Daily - Mon Nov 17, 12:22PM CST
Stocks improved Monday afternoon, turning mixed. They have wavered amid news of Japan falling into a recession and a round of merger and acquisition activity. The Dow Jones industrial average rose 0.1%, lifted by UnitedHealth Group (UNH). The broader...
HAS: 55.98 (-0.39), LNKD: 223.74 (+0.46), FB: 74.59 (+0.35), UNH: 98.25 (+1.78), ILMN: 189.21 (+6.30), MIK: 21.83 (+0.18), DWA: 22.35 (+0.04)
Strength Seen in Geron (GERN): Stock Surges 19.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 8:25AM CST
Geron (GERN) was a big mover last session, with shares surging over 19% on the day.
BIIB: 305.77 (+3.35), GERN: 3.08 (+0.10), ILMN: 189.21 (+6.30), AFFX: 9.50 (+0.21)
Sequenta Enters Agreement with Illumina on In Vitro Diagnostic Kit for Sequencing-Based Minimal Residual Disease Testing
Business Wire - Mon Nov 17, 8:01AM CST
Sequenta, Inc., a biotechnology company developing clinical diagnostics based on immune cell receptor genes, today announced that the company has entered into an agreement with Illumina, Inc. (NASDAQ: ILMN). The purpose of the agreement is to commercialize an in vitro diagnostic (IVD) kit that will enable clinical laboratories to utilize Sequenta's next-generation sequencing (NGS)-based minimal residual disease (MRD) detection and quantification technology.
ILMN: 189.21 (+6.30)
Medical Stocks Tumble But Most Of IBD 50 Trading Well
at Investor's Business Daily - Fri Nov 14, 5:47PM CST
A few medical leading stocks have slid, but otherwise the IBD 50 remained in good shape last week. Illumina (ILMN) and Akorn (AKRX) have fallen below their buy points, while Alexion Pharmaceuticals (ALXN) and Celgene (CELG) exhibited some weakness of...
AKRX: 38.78 (+0.89), ALXN: 189.60 (+2.82), FFIV: 128.49 (+0.63), ILMN: 189.21 (+6.30), SPR: 41.49 (+0.42), AAPL: 114.66 (+0.67), ATHM: 41.81 (-1.04), BITA: 94.12 (+4.74), CELG: 105.97 (+1.61)
Stock Market Treads Water; Earnings Drive BitAuto
at Investor's Business Daily - Fri Nov 14, 3:21PM CST
Stocks struggled for direction for most of the day Friday amid upbeat data on retail sales and consumer sentiment. But the main indexes ultimately ended mildly higher. The Nasdaq edged up 0.2%, thanks to strength in software and solar issues. But...
NTES: 100.72 (-0.40), ILMN: 189.21 (+6.30), BITA: 94.12 (+4.74), CELG: 105.97 (+1.61)
Stocks Mixed; Amazon Jumps On Book Deal
at Investor's Business Daily - Fri Nov 14, 12:32PM CST
Stocks were mixed, but gained a small amount of ground in afternoon trading Friday. A better-than-expected retail sales report lifted Wall Street spirits in the stock market today. The Nasdaq gained 0.1%; the Dow Jones industrial average dropped...
BIIB: 305.77 (+3.35), AMZN: 328.43 (+5.38), HAL: 49.75 (+0.52), ILMN: 189.21 (+6.30), BITA: 94.12 (+4.74), BHI: 65.91 (+0.68), CELG: 105.97 (+1.61)
Sarepta Initiates Dosing for Study Evaluating Eteplirsen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:40PM CST
Sarepta (SRPT) announced that it has enrolled the first patient in an open label study on eteplirsen in non-ambulant Duchenne muscular dystrophy patients.
RNA: 11.37 (-0.42), SRPT: 15.57 (+0.23), ILMN: 189.21 (+6.30), CELG: 105.97 (+1.61)
Illumina Falls 1.03% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Nov 13, 4:25PM CST
Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $183.84 to a high of $191.62. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $186.11 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ILMN: 189.21 (+6.30)
Ligand/Glaxo Seek EU Nod for Severe Aplastic Anemia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:00PM CST
Ligand Pharma (LGND) announced the submission of a Marketing Authorisation Application to the European Medicines Agency by its partner GlaxoSmithKline for Revolade.
LGND: 57.70 (+0.75), ILMN: 189.21 (+6.30), GSK: 46.16 (+0.28), CELG: 105.97 (+1.61)
Qiagen Partners with Novartis for Companion Diagnostics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 1:20PM CST
Qiagen N.V. (QGEN) has signed a master collaboration agreement with Novartis.
ICUI: 86.41 (+0.71), ILMN: 189.21 (+6.30), QGEN: 23.83 (+0.34), NVS: 95.43 (+1.05)
Alnylam Adds Hepatic Infectious Disease Drugs to Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:40PM CST
Alnylam (ALNY) expands its hepatic infectious disease pipeline with two new candidates, ALN-HDV (hepatitis delta viral) and ALN-PDL (chronic liver).
BIIB: 305.77 (+3.35), ALNY: 91.25 (+2.27), ILMN: 189.21 (+6.30), AMAG: 35.78 (+1.02)
Brand Timbre Develops Audio-Identity Platform for World's Largest Genomics Company
Marketwired - Wed Nov 12, 6:00AM CST
Brand Timbre LLC, a strategic sonic branding agency, has completed work on the first stage of a comprehensive audio-branding initiative for Illumina Inc. Illumina is an industry-leading life-sciences company that designs, develops and manufactures DNA and genetics sequencing machines used in labs throughout the world. Brand Timbre's multi-phase project includes an audio-branding strategy, an audio-identity profile that defines Illumina's sound, an audio logo, and product-sonification (sound design) assets for Illumina's sequencing instruments.
ILMN: 189.21 (+6.30)
Critical Alerts For Achillion Pharmaceuticals, Celldex Therapeutics, Kandi Technologies, Illumina and Advanced Micro Devices Released By InvestorsObserver
PR Newswire - Tue Nov 11, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for ACHN, CLDX, KNDI, ILMN and AMD.
KNDI: 14.82 (+0.65), AMD: 2.66 (-0.01), ACHN: 13.59 (+0.27), CLDX: 17.66 (-0.59), ILMN: 189.21 (+6.30)
Achillion Pharmaceuticals (ACHN) Looks Strong: Stock Up 27.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 7:44AM CST
Achillion Pharmaceuticals (ACHN) was a big mover last session, as the company saw its shares surge a little over 27% on the day
HSKA: 15.00 (-0.05), ACHN: 13.59 (+0.27), ILMN: 189.21 (+6.30), AFFX: 9.50 (+0.21)
Global Preimplantation Genetic Diagnosis (PGD for Chromosomal Aberrations, Aneuploidy Screening, Gender Selection, Single Gene Disorders, HLA Typing and X-linked Diseases) Market - Trends and Forecast to 2020
M2 - Tue Nov 11, 4:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/sm76mf/preimplantation) has announced the addition of the "Preimplantation Genetic Diagnosis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. Since the last two decades, preimplantation genetic diagnosis (PGD) has been used to detect chromosomal aneuploidy in low prognosis patients who undergo in-vitro fertilization (IVF). PGD is now being used to detect a broader range of indications due to advancements in the medical technology. These indications include chromosomal aberrations, genetic abnormalities, gender selection, HLA typing, X-linked diseases and single gene diseases. Demand for PGD is continuously increasing in patients who undergo IVF in the hope that it would improve the probability of live birth and reduce the chances of disabilities and genetic disorders in the offspring. This report provides in-depth analysis of the preimplantation genetic diagnosis market and its test types across various regions. Stakeholders in the report include diagnostic laboratories that provide PGD services, companies involved in the production of diagnosis kits and sequencers for PGD, and prospective market players planning to enter the market. The report comprises executive summary, which offers a market snapshot that covers the overall information about various types of tests in the PGD market. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Preimplantation Genetic Diagnosis Market Overview Chapter 4 Global Preimplantation Genetic Diagnosis Market, by Test Type Chapter 5 Preimplantation Genetic Diagnosis Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles Companies Mentioned: - Genea Ltd. - Genesis Genetics - Illumina, Inc. - Laboratory Corporation of America Holdings (LabCorp) - Natera, Inc. - PerkinElmer, Inc. - Quest Diagnostics, Inc. - Reproductive Genetics Institute - Reprogenetics LLC For more information visit http://www.researchandmarkets.com/research/sm...plantation
DGX: 63.45 (+0.41), LH: 100.71 (+0.63), ILMN: 189.21 (+6.30), PKI: 43.60 (+0.21)
Winning Stock Picking Ideas from Last Week's Jobs Report - Screen of the Week
Kevin Matras - Zacks Investment Research - Tue Nov 11, 3:18AM CST
Winning Stock Picking Ideas from Last Week's Jobs Report - Screen of the Week
CST: 42.76 (+0.85), JACK: 71.27 (+0.98), IHS: 132.26 (+1.06), ILMN: 189.21 (+6.30)
